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This study was based on the preparation, characterization, and animal in vivo experiments performed to evaluate nanoparticles of
poly(𝜀-caprolactone) (PCL) and chitosan as carriers of enoxaparin.The nanoparticles were characterized and presented satisfactory
results in terms of size, polydispersity, and encapsulation efficiency. Anticoagulant activity of the nanoparticles was maintained
for 14 hours when the administration was subcutaneous; however no activity was observed after oral administration. There was a
significant reduction in thrombus size, in vivo, for both free and encapsulated enoxaparin in comparisonwith the control group after
subcutaneous administration. Oral administration results however were indifferent. In conclusion, the double emulsion method
w/o/w was efficient for enoxaparin encapsulation, producing spherical nanoparticles with high encapsulation efficiency. For in
vivo studies, the encapsulated enoxaparin showed a sustained anticoagulant activity for a higher period of time compared to free
enoxaparin, with an antithrombotic effect when administered subcutaneously.
1. Introduction
Deep vein thrombosis (DVT) is one of the most important
public health problems, with an annual incidence estimated
as 67 per 100.000 individuals in the population [1, 2]. Heparin
is a drug with antithrombotic action, widely used since
1930 [3]. Low molecular weight heparin (LMWH) exhibits
superior pharmacodynamic and pharmacokinetic properties
compared to heparin and shows low affinity for plasma and
cellular proteins. Therefore, LMWH exhibited a more predi-
ctable and reproducible anticoagulant response than heparin
and did not require monitoring in most clinical situations [4].
The new direct oral anticoagulants available present limi-
tations of antidotes for anti-Xa drugs and lack laboratory tests
which would be used in special situations such as bleeding or
emergency procedures [5]. Adherence to treatment is indeed
a challenge in clinical practice for medications with continu-
ous daily use. Therefore, the possibility of drugs with a pro-
longed half-life which do not increase bleeding represent a
good opportunity for a better management of those patients.
A sustained release drug is intended tomaintain the effect
of the active component in the target tissue, by solubilizing
this active component, to improve the physical and chemical
stability of therapeutic agents, minimize side effects, and
reduce toxicity [6–8]. In a sustained release system, the active
ingredient encapsulated in a matrix must have the following
characteristics: enabling modeling of the desired shape and
release of the active substance by appropriate mechanisms,
adequate stability, and low toxicity including any degradation
product [8, 9]. Furthermore, reduced side effects, increased
bioavailability, and decreased number of required doses of
the therapeutic agent are important issues [9, 10]. PCL is
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semicrystalline polyester, biodegradable, and biocompatible.
This, along with the mechanical properties and relatively low
cost of PCL, renders this polymer very attractive for bio-
medical devices [11].
In the pharmaceutical area, chitosan has beenwidely used
in drug delivery systems [12]. In addition to being a biocom-
patible polymer, biodegradable, and nontoxic, chitosan has
interesting biological properties such as antimicrobial activ-
ity, potent topical analgesic action, acceleration of the healing
process, and bioadhesion to mucous membranes and skin
[13].
The preparation of heparin encapsulated in nanoparticles
by the double emulsion method water in oil in water (w/o/w)
using biodegradable polymers such as PCL and PLGA alone
or in combination with other biodegradable polymers (Eud-
ragit RS and RL) has been successfully used. These studies
showed reproducible results regarding diameter, encapsula-
tion efficiency, and anti-Xa activity in vitro and in animal
models [14–17].
The use of animal models to investigate DVT is advan-
tageous enabling the evaluation of new pharmaceutical
approaches for prophylaxis and treatment and of how these
approaches can interfere in initiation, propagation, and reso-
lution of venous thrombus.
In this study we produced and characterized nanoparti-
cles of PCL and chitosan as carriers of LMWH, enoxaparin.
We also investigated the antithrombotic effect through oral
and subcutaneous administration in animalmodels of venous
thrombosis.
2. Methods
2.1. Preparation of Chitosan-PCL Nanoparticles with Enoxa-
parin. Nanoparticles were prepared with a biodegradable
polymer PCL (Aldrich) and coated with the natural polymer
chitosan (105 g/mol/∼81% acetylation, Polymar). The prepa-
ration of nanoparticles with and without enoxaparin was per-
formed by the modified double emulsion method. An aque-
ous solution (200𝜇l) of enoxaparin (Clexane 100mg/mL),
1mL of deionized water, and 0.5% of polyvinyl alcohol (PVA)
was first emulsified with an organic phase containing 10mL
of ethyl acetate and 60mg of PCL under stirring for 1 minute
at 6000 rpm to form a water/oil emulsion. This emulsion
was then transferred to a vessel containing 50.1ml of deion-
ized water, 1% PVA, 0.9% NaCl, and 9.9mL of chitosan solu-
tion (2mg/mL) and homogenized under mechanical stirring
at 10000 rpm for 1.5 minutes, forming a double emulsion
(water/oil/water). After this period the double emulsion was
transferred to a round bottom flask and the solvent evapo-
rated at a temperature of 28∘C in a route evaporator to a final
volume of 10mL.
2.2. Particle Size and Zeta Potential. The average particle size,
polydispersity index (PDI), and zeta potential weremeasured
through photon correlation spectroscopy (PCS) by Zeta
Sizer Malvern (Malvern Instruments Corp). Measurements
were performed in KCl solution (1mM). The preparation
stability was measured weekly; for this, the dispersions was
maintained at 4∘C during 50 days.
2.3. Scanning Electron Microscopy (SEM). The particles were
characterized by Scanning Electron Microscopy (SEM, Jeol
JSM-6360LV) at a voltage of 20 kV after prior coating with
gold/palladium under vacuum by sputtering using a BAL-
TEC apparatus. Secondary electron images were obtained.
2.4. Encapsulation Efficiency. The encapsulation efficiency
(EE) of enoxaparin encapsulated in PCL-chitosan nanopar-
ticles was determined by the modified Azure II colorimetric
method [18]. Particle dispersion was filtered in a Microcon
centrifugal filter device containing ultrafiltrationmembranes
(MWCO 100.000, Millipore). The filtrate was mixed with
Azure II solution (0.05mg/mL) (1 : 10) at room temperature
and the sample was measured at 𝜆 = 500 nm using UV-Vis
spectrophotometer (Agilent 8453).The filtrate was assayed to
determine the concentration of the nonencapsulated drug.
Encapsulation efficiency (EE%) was calculated using the
following equations [16]:
% non-encapsulated drug
= ([enoxaparin] in filtered solution[enoxaparin] initial ) × 100,
(EE%) = 100 −% non-encapsulated enoxaparin.
(1)
2.5. Anticoagulant Action Measured by Anti-Xa Activity in
Normal Rats. Male Wistar rats, from CEMIB-UNICAMP,
were used respecting the Brazilian Law of Animal Exper-
iments. The experimental protocol was approved by the
University Committee on Animal Research.
The experimentswere performedwith 32maleWistar rats
at 5–7 weeks of age, divided into four groups. The aqueous
enoxaparin suspension encapsulated in PCL-chitosan nano-
particles (5000 IU/kg), empty nanoparticles (5000 IU/Kg),
free enoxaparin (500 IU/Kg), and saline solutionwere admin-
istered orally or by subcutaneous injection. The anti-Xa
activity (Top-IEL 500) was determined in plasma samples
at 1, 2, 3, 6, 8, 10, 12, and 14 hours after administration in
each group. Blood samples were withdrawn from the tail vein
into a vial containing sodium citrate, which was gently mixed
before centrifugation for 15minutes at 600 g to obtain plasma.
Anti-Xa activity was determined by a chromogenic sub-
strate assay (Berichrom Heparin, Siemens), with detection
limit of 0.05 IU/mL. In this evaluation, enoxaparin was ana-
lyzed as a complex with antithrombin present in the sample.
The concentration of this complex is dependent on the avail-
ability of the endogenous antithrombin in the animal. Factor
Xa is neutralized by the antithrombin-enoxaparin complex.
The residual Xa factor is quantified using a synthetic chro-
mogenic substrate.
2.6. Antithrombotic Activity in a Venous Thrombosis Animal
Model. The experiments were performed with 48 male Wis-
tar rats of 5–7weeks of age, divided into four groups of six ani-
mals.The animals were anesthetized by intraperitoneal injec-
tion of a solution of ketamine (75mg/Kg) (Ketalar, Parke-
Davis, Brazil) and xylazine (10mg/Kg) (Unia˜o Quı´mica
Farmaceˆutica Nacional S/A, Brazil).
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Table 1: Values of diameter, polydispersity index, and zeta potential of three dispersions of enoxaparin nanoparticles.
Particles dispersion Diameter (nm) Polydispersity index Zeta potential (mV)
1 512.5 0.458 +30.7
2 526.8 0.401 +32.3
3 499.2 0.369 +29.8
Mean 512.8 0.409 +30.9
Standard deviation 13.8 0.04 1.3
Enoxaparin encapsulated in PCL-chitosan nanoparticles
(5000 IU/kg), empty nanoparticles, free enoxaparin (500 IU/
Kg), and saline solution were administered subcutaneously
or orally. One hour (subcutaneous) or six hours (oral) after
administration, the abdomen of the animals was surgically
opened and thrombosis was induced according to the modi-
fied method of Reyers et al. (1980) and Carvalho et al. (1992)
and modified method of Herbert et al. (1992) [19–21]. Briefly,
the cava vein was isolated and its branches were ligated up
to 1.5 cm distal to the left renal vein confluence. Ligature
of the cava vein was carried out using 4-0 silk thread at a
point immediately caudal to the left renal vein. After ligation,
thromboplastin solution (Thromborel S; Siemens; ≤60mg/
mL) was injected at a concentration of 5mg/kg body weight
of the animal in the attached segment. Twenty minutes after
induction, the abdomen was opened to verify the presence
of thrombus. When present, the thrombus was removed and
weighed immediately and then after drying for 24 h at 37∘C.
2.7. Statistical Analysis. The results of encapsulation effi-
ciency, average diameter, and zeta potential were analyzed
and reported as mean ± standard deviation.
Anti-Xa activity and comparison between 4 independent
groups were analyzed by the nonparametric Kruskal-Wallis
test; a value of 𝑃 < 0.05 was considered statistically signi-
ficant.
3. Results
3.1. Preparation of Chitosan-PCL Nanoparticles with Enoxa-
parin and Stability. Table 1 shows the characterization of
PCL-chitosan nanoparticles with enoxaparin. The double
emulsion and solvent evaporation method showed being
reproducible.
Furthermore, there were no significant changes in the size
and zeta potential of PCL-chitosan nanoparticles with and
without enoxaparin, evidencing the stability of these particles
for a period of 50 days at 4∘C, as shown in Figures 1(a) and
1(b). This result demonstrates that both particles are good
carrier systems. The PCL-chitosan nanoparticles produced
by w/o/w double emulsion showed an entrapment efficiency
of 99.04 ± 0.001%, therefore demonstrating being a good
method for hydrophilic drug encapsulation.
The SEM images of the PCL nanoparticles showed spher-
ical and homogeneous particles (Figure 2). The morphology
did not change after enoxaparin encapsulation, as shown in
Figure 2(b).
3.2. Anticoagulant Activity Measured by Anti-Xa Activity in
Normal Rats. Figure 3 shows the results of anti-Xa activity
in rat plasma samples collected in determined periods after
subcutaneous injection of saline solution, free enoxaparin
(500UI/Kg), and nanoparticles with and without enoxaparin
(5000UI/Kg). After administration of free enoxaparin there
was a peak of anti-Xa activity after 1 hour (0.37 IU/ml), which
disappeared within 6 hours. When the PCL-chitosan nano-
particles with enoxaparin were administered, there was a
peak of anti-Xa activity after 3 hours (1.8 IU/ml), which was
much higher than that obtained with free enoxaparin and
remained constant for 10 hours. This result was significantly
higher when compared to free enoxaparin (𝑃 = 0.0043).
After 14 hours a remaining anti-Xa activity of 0.6 IU/mL was
observed. Empty nanoparticles (without enoxaparin) exhibit
no anti-Xa activity, identical to that observed with saline
solution.
For all groups evaluated, oral administration showed no
anti-Xa activity in rats plasma, indicating no antithrombotic
effect of these formulations.
3.3. Antithrombotic Effect in a Venous Thrombosis Animal
Model. Figure 4 shows the analysis of the antithrombotic
effect, as measured by thrombus weight, in animals treated
with saline solution, free enoxaparin, and nanoparticles with
enoxaparin (50mg/Kg) administered subcutaneously. There
was a significant lower thrombus weight in the treated groups
in comparison to control (𝑃 = 0.0005) (Figure 4).
Figure 5 shows the analysis of the antithrombotic effect, as
assessed by thrombus weight after animals were treated orally
with saline solution, empty nanoparticles, and nanoparticles
with enoxaparin.The results showed a similar thrombiweight
and no significant difference between the groups (𝑃 =0.0757).
4. Discussion
Thedouble emulsionmethod and solvent evaporation used in
this study were able to produce relatively homogeneous and
spherical nanoparticles. These properties are important for
nanoparticle quality. A major difficulty encountered during
enoxaparin encapsulation is the hydrophilic nature of this
anticoagulant, which leads to greater diffusion of the drug
to the external phase before the precipitation of the polymer,
thus reducing encapsulation efficiency [22]. The comparison
between the size of our nanoparticles and those described in
another study showed similar results [23]. The nanoparticles
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Figure 1: Diameter, polydispersity index, and zeta potential of the nanoparticles during 50 days: (a) empty nanoparticles; (b) nanoparticles
containing enoxaparin.
(a) (b)
Figure 2: SEM microscopy of nanoparticles: (a) empty nanoparticles; (b) nanoparticles containing enoxaparin.
were stable for over 50 days regarding size and polydispersity
index. Regarding encapsulation efficiency, results of 99.04%
on average reinforce the idea that the natural polymer chi-
tosan used for coating the nanoparticles is very appropriate
for encapsulation of hydrophilic molecules, especially when
this dispersion of particles comes into contact with the
stomach mucosa, which has acid pH.
Our in vivo results evidenced that anti-Xa activity was
higher with the use of nanoparticles containing enoxaparin in
comparison to free enoxaparin. A possibility is that the dose
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Figure 4: Antithrombotic effect shown through the comparison of
thrombus weight of animals after surgery and subcutaneous treat-
ment (𝑛 = 6 animals per group). ∗𝑃 = 0.0005.𝑃 value was calculated
using ANOVA.
of enoxaparin used in the encapsulated nanoparticles was 10
times higher than the dose of free enoxaparin. We elected
this high dose of enoxaparin as encapsulation could com-
promise the stability, or a sustained and prolonged release
could require a higher concentration of the drug. We have
previously demonstrated a slow release of encapsulated PCL-
enoxaparin in vitro during the first 24 hours [17].
The controlled release characteristic of nanomaterials
enabling drug liberation for a long period of time and
preserving the pharmacological effect without reaching the
toxicity range is interesting. This result of prolonged anti-Xa
(saline) nanoparticles
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Figure 5: Comparison of thrombus weight in animals after surgery
and oral treatment. 𝑁 = 6 animals per group. 𝑃 value calculated
through ANOVA.
activitywith the use of enoxaparin encapsulated in nanoparti-
cles should be valuable, as a drug that has a preserved survival
rate in safe doses is desirable in clinical practice.
The oral administration of enoxaparin, free or encap-
sulated into nanoparticles, demonstrated no anticoagulant
effect, with no anti-Xa activity up to 14 hours, suggesting that
enoxaparin was not absorbed along the gastrointestinal tract
by premature degradation or failure in absorption [24].
Thus, our results demonstrate that encapsulation of
enoxaparin in PCL nanoparticles with chitosan was not able
to avoid this degradation process or provide gastrointestinal
absorption. Sun et al. (2010) recently reported that complexes
of polyelectrolytes with chitosan and enoxaparin with similar
diameters provided an anticoagulant activity in rats, when
administered orally [23]. However, aPTT was the method
used to measure anticoagulant activity of nanoparticles and
showed an increase of only 2 seconds when compared to the
saline control. The results did not include the concentration
of enoxaparin nanoparticles either. Moreover, a study using
PCL, PVA, and Eudragit nanoparticles with tinzaparin (200
to 600 IU/Kg) with a diameter of approximately 400 nm
showed oral absorption and anticoagulant activity in rabbits,
demonstrated by an increase in anti-Xa activity in plasma
[15]. Jiao et al. (2002) published a study using heparin and
PCL and PLGA and Eudragit RS and/or RL, obtaining minor
particles for oral delivery in rabbits.These nanoparticles were
shown to be functional verified through anti-Xa activity and
aPTT [16]. These results suggested that Eudragit or modified
chitosan could probably contribute decisively to oral absorp-
tion. Pazzini et al. (2015) published a study using PCL and
enoxaparin for subcutaneous route. Beyond differences in
the particle properties, such as negative potential and no use
of chitosan, some differences in the biological activity were
verified [17]. The PCL coated chitosan was more efficient for
reaching the maximum of activity at 3 h (1.8 anti-XaUI/mL)
andwithout chitosan themaximum value was at 6 h (0.6 anti-
XaUI/mL). The release in the first case lasted approximately
14 h and in the second one zero at that time.
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Induction ofDVTusingmodels of stasis and hypercoagu-
lability enables the development of homogeneous and repro-
ducible thrombi, accelerating the process, which facilitates
the analysis of the effect of antithrombotic drugs. In our study
the reduction of thrombus size after the use of subcuta-
neous nanoparticles with enoxaparin confirmed the in vivo
antithrombotic effect. This result is important for excluding
the hypothesis of no effect of enoxaparin nanoparticles
administered orally due to the encapsulation.
Our results also demonstrated that oral administration of
free or encapsulated enoxaparin presented no antithrombotic
effect.These results confirm the laboratorial effects measured
by anti-Xa activity observed in these animal models. There-
fore, these results reinforce the hypothesis that enoxaparin
was either prematurely degraded or not absorbed.
Therefore, particles with nanometric diameter (500 nm)
and positively charged were obtained by the double emulsion
method and solvent evaporation. The method was repro-
ducible and, in addition, the obtained particles were stable for
50 days. High encapsulation efficiency (∼99%) was obtained
for the hydrophilic drug enoxaparin indicating that the
method is suitable for this molecule encapsulation.
The study showed that nanoparticles with enoxaparin
exhibit anticoagulant and antithrombotic activity in DVT rat
models when administered subcutaneously.
The addition of chitosan did not provide an antithrom-
botic or anticoagulant effect for oral administration of these
nanoparticles in rats.This resultmay be due to nonabsorption
of nanoparticles or early degradation of enoxaparin in the
gastrointestinal tract. In the literature, chitosan was used as
an effective hemostatic agent in animal models of splenic
and liver injury. Studies suggest that chitosan may enhance
hemostasis by cell-cell contact or by the formation of a lattice,
which entraps cells to form an artificial clot [25]. In our
study, chitosan was used to recover the nanoparticles, with
a minimum surface of contact with the blood stream due
to nanostructures. Indeed, an in vivo evaluation with empty
nanoparticles was performed and similar anti-Xa activity was
observed when compared to controls (saline), suggesting no
effects on hemostasis, as shown in Figure 3.
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